Safety of Imovax Polio in Chinese Infants and Children

Inclusion Criteria: * Group 1: Aged 18 months (18-20 months) on the day of inclusion * Group 2: Aged 2 months (56-70 days) on the day of inclusion Exclusion Criteria: * Participation in another clinical trial in the 4 weeks preceding the trial vaccination * Planned participation in another clinical trial during the present trial period * Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy * Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances * Chronic illness at a stage that could interfere with trial conduct or completion * Blood or blood-derived products received in the past 3 months (for Group 1) or since birth (for Group 2) * Any vaccination in the 4 weeks preceding the trial vaccination (except BCG and Hepatitis B \[Hep B\] for Group 2) * Vaccination planned in the 4 weeks following the trial vaccination * Group 1: Previous booster vaccination against the poliomyelitis infection with the trial vaccine or with another vaccine. * Group 2: Previous vaccination against the poliomyelitis infection with the trial vaccine or with another vaccine. * History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically) * Clinical or serological evidence of systemic illness including Hepatitis B, C and HIV * Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination * History of/current seizures * Febrile illness (axillary temperature ≥ 37.4°C) or acute illness on the day of inclusion